Short-term γ-aminobutyric acid antagonist treatment improves long-term sleep quality, memory, and decision-making in a Down syndrome mouse model
SLEEP · 2025
DOI: 10.1093/sleep/zsae300 ↗Kurz gefasst
Fachartikel in der Zeitschrift SLEEP, 2025. Verfasst von Elsa C Pittaras und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Stanford University, Stanford, CA, USA. Hauptthemen laut MEDLINE: Down Syndrome, Decision Making, GABA Antagonists, Sleep Quality. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: NIMH NIH HHS, Non-Federal funding.
Themen: Schlaf
Abstract (Originalsprache)
Down syndrome (DS) is a common genetic condition affecting people worldwide. It involves cognitive disabilities for which there are no drug therapies. The Ts65Dn mouse model of DS shows cognitive impairment due to a reduction in neuron number and connectivity as well as excessive neuronal activity, as γ-aminobutyric acid (GABA) antagonist treatment restores memory in these mice. Our study showed the effects of GABA antagonist treatment on sleep and decision-making in Ts65Dn mice. We administered a daily, low oral dose of pentylenetetrazol (PTZ) in milk to Ts65Dn mice for 17 days. Decision-making was tested with and without PTZ treatment. Short and long-term memories were tested before, immediately after, and 1 month following PTZ treatment. Electro-encephalography was also recorded at these three time points to study the effect of the treatment on sleep. We showed that PTZ treatment improved long-term recognition, but not short term memory and led to more Ts65Dn mice showing safer decision-making behavior. PTZ treatment showed a moderate and only global beneficial effect on sleep by decreasing the global amount of wake and increasing non-rapid eye movement sleep in the Ts65Dn mice, which may explain the observed cognitive improvements. These results bring new knowledge on the role of GABA in sleep, memory consolidation, and decision-making abilities in DS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Stanford University, Stanford, CA, USA.
- Stanford Law School, Stanford University, Stanford, CA, USA.
- The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
- School of Biomedical Sciences, University of Melbourne, Parkville, Victoria, Australia.
- Somnivore Pty. Ltd., Bacchus Marsh, Victoria, Australia.
- Department of Human Biology, School of Humanities and Sciences, Stanford University, Stanford, CA, USA.
ORCID-Profile: Elsa C Pittaras, Rebecca Pizzitola, Natalie Tan
Förderung
- NIMH NIH HHS
- Non-Federal funding
Zitieren
APA
Pittaras, E. C., Artal, J. M., Ajibola, G., Allocca, G., Bennett, M., Camargo, A., Carpio, A., Gessner, N., Hinton, M., Pizzitola, R., Tan, N., Zhang, E., Zhong, A., & Heller, H. C. (2025). Short-term γ-aminobutyric acid antagonist treatment improves long-term sleep quality, memory, and decision-making in a Down syndrome mouse model. SLEEP. https://doi.org/10.1093/sleep/zsae300
Vancouver
Pittaras EC, Artal JM, Ajibola G, Allocca G, Bennett M, Camargo A, et al. Short-term γ-aminobutyric acid antagonist treatment improves long-term sleep quality, memory, and decision-making in a Down syndrome mouse model. SLEEP. 2025. doi:10.1093/sleep/zsae300
BibTeX
@article{Pittaras2025,
author = {Pittaras, Elsa C and Artal, Jonathan M and Ajibola, Grace and Allocca, Giancarlo and Bennett, Mia and Camargo, Alexandra and Carpio, Angelica and Gessner, Nicholas and Hinton, Myles and Pizzitola, Rebecca and Tan, Natalie and Zhang, Evelyn and Zhong, Alan and Heller, Horace C},
title = {Short-term γ-aminobutyric acid antagonist treatment improves long-term sleep quality, memory, and decision-making in a Down syndrome mouse model},
journal = {SLEEP},
year = {2025},
doi = {10.1093/sleep/zsae300}
}
EUVIMED